Efficacy of Acupuncture in the Treatment of Fibromyalgia

NCT ID: NCT00010764

Last Updated: 2008-03-07

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Study Classification: INTERVENTIONAL
• Study Start Date: 2000-09-30
• Study Completion Date: 2002-07-31

Brief Summary

Fibromyalgia (FM), one of the most common rheumatic conditions, is a condition of unknown etiology characterized by widespread muscle pain and stiffness. Treatment is generally unsatisfactory and most randomized, controlled treatment trials have been unable to demonstrate a sustained effective intervention. A single, brief trial of electroacupuncture demonstrated remarkable improvement among patients with FM, although lasting effects were not evaluated. Nonetheless, the recently published National Institutes of Health Consensus Development Statement on Acupuncture says "musculoskeletal conditions such as fibromyalgia, myofascial pain ....are conditions for which acupuncture may be beneficial". Thus, 96 patients will be recruited from a referral clinic for fatigue for a 12 week (24 treatments) trial. These patients will be randomized into 3 control groups and 1 "true" acupuncture group. The control groups will consist of a group receiving acupuncture treatment for an unrelated condition (morning sickness), a group receiving needle insertion at non-channel, non-point locations, and a "true" placebo group. This latter group will have acupuncture needle guides tapped on the skin, then needles tapped. Thus, the specific aims of this study are to 1) evaluate the short and long term efficacy and side effects of a 12 week randomized, controlled trial of bi-weekly acupuncture in the treatment of FM; 2) establish the most useful and scientifically sound control group for studies of acupuncture using FM as a model for conditions characterized by chronic pain; 3) use both subjective and objective measures of overall health and pain to determine the optimal time length of treatment; and 4) examine the concordance of allopathic and acupuncture-based measures of outcome. For the purposes of this study, subjects will be asked to complete a unique set of study measures at enrollment, at 4, 8, and 12 weeks, and then again at 1 and 6 months post-treatment. Our primary outcomes will be patient global assessment, subjective pain, and mean number of tender points. Secondary outcomes will be pain threshold, analgesic use, physician global assessment, functional status, sleep, psychological distress, and fatigue. Thus, this trial will have both immediate and longer term implications for the scientific study of acupuncture as well as the clinical care of the estimated 5 million patients with FM in the US. From a methodological point of view, the proposed trial will establish the most appropriate methods for choosing a control group should larger trials be conducted, suggest the optimum duration of treatment, and evaluate the utility of diverse allopathic and alternative outcome measures. Of equal importance, however, this research will test and potentially establish the effectiveness of acupuncture.

Detailed Description

See brief summary

Conditions

Fibromyalgia

Study Design

• Allocation Method: RANDOMIZED
• Primary Study Purpose: TREATMENT

Interventions

Acupuncture

Intervention Type: PROCEDURE

Eligibility Criteria

Inclusion Criteria

• Non-pregnant, non-nursing
• Have FM as diagnosed according to the 1990 ACR guidelines at some time but not necessarily currently
• Have a global pain score of >4 on a visual analog scale (VAS, 1=no pain, 10=worst pain)
• Not have another concurrent medical condition associated with significant diffuse neuropathic, musculoskeletal, or joint pain such as diabetic neuropathy, systemic lupus erythematosus, rheumatoid arthritis or severe multi-joint degenerative joint disease
• Not have a history of, or any clinical indication of, a bleeding diathesis
• Not be using narcotics on daily, regular basis
• Not have previously received acupuncture (i.e., be acupuncture naive)
• Not be concurrently participating in any other clinical trials
• Try to stay on a stable medical regiment during the entire course of treatment
• Willing to undergo randomization
• Live within one hour of a treatment site and able to come on a regular basis for treatments
• Not have a pacemaker
• Be able to give consent

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Center for Complementary and Integrative Health (NCCIH)

NIH

Sponsor Role: lead

Principal Investigators

Debra S. Buchwald, MD

Role: PRINCIPAL_INVESTIGATOR

Harborview Injury Prevention and Research Center

Locations

Harborview Medical Center

Seattle, Washington, United States

Countries

United States

Other Identifiers

R01AT000003-01

Identifier Type: NIH

Identifier Source: org_study_id

View Link

NCT00009139

Identifier Type: -

Identifier Source: nct_alias